These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26252055)

  • 1. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.
    Buim ME; Fanelli MF; Souza VS; Romero J; Abdallah EA; Mello CA; Alves V; Ocea LM; Mingues NB; Barbosa PN; Tyng CJ; Chojniak R; Chinen LT
    Cancer Biol Ther; 2015; 16(9):1289-95. PubMed ID: 26252055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.
    Kondo Y; Hayashi K; Kawakami K; Miwa Y; Hayashi H; Yamamoto M
    BMC Cancer; 2017 May; 17(1):311. PubMed ID: 28468669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
    Kalikaki A; Politaki H; Souglakos J; Apostolaki S; Papadimitraki E; Georgoulia N; Tzardi M; Mavroudis D; Georgoulias V; Voutsina A
    PLoS One; 2014; 9(8):e104902. PubMed ID: 25137394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients.
    Mohamed Suhaimi NA; Foong YM; Lee DY; Phyo WM; Cima I; Lee EX; Goh WL; Lim WY; Chia KS; Kong SL; Gong M; Lim B; Hillmer AM; Koh PK; Ying JY; Tan MH
    Mol Oncol; 2015 Apr; 9(4):850-60. PubMed ID: 25605225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.
    Li Y; Monzo M; Moreno I; Martinez-Rodenas F; Hernandez R; Castellano JJ; Canals J; Han B; Muñoz C; Navarro A
    Int J Colorectal Dis; 2020 May; 35(5):805-813. PubMed ID: 32088737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran.
    Koochak A; Rakhshani N; Karbalaie Niya MH; Tameshkel FS; Sohrabi MR; Babaee MR; Rezvani H; Bahar B; Imanzade F; Zamani F; Khonsari MR; Ajdarkosh H; Hemmasi G
    Asian Pac J Cancer Prev; 2016; 17(2):603-8. PubMed ID: 26925650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.
    Denis JA; Patroni A; Guillerm E; Pépin D; Benali-Furet N; Wechsler J; Manceau G; Bernard M; Coulet F; Larsen AK; Karoui M; Lacorte JM
    Mol Oncol; 2016 Oct; 10(8):1221-31. PubMed ID: 27311775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
    Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S
    Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
    Vanova B; Kalman M; Jasek K; Kasubova I; Burjanivova T; Farkasova A; Kruzliak P; Busselberg D; Plank L; Lasabova Z
    Clin Exp Med; 2019 May; 19(2):219-224. PubMed ID: 30661213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer.
    Raimondi C; Nicolazzo C; Gradilone A; Giannini G; De Falco E; Chimenti I; Varriale E; Hauch S; Plappert L; Cortesi E; Gazzaniga P
    Cancer Biol Ther; 2014 May; 15(5):496-503. PubMed ID: 24521660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between
    Aktar S; Islam F; Cheng T; Gamage SMK; Choudhury IN; Islam MS; Lu CT; Hamid FB; Ishida H; Abe I; Xie N; Gopalan V; Lam AK
    Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
    Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.